Glucoside detergents are successfully used for membrane protein crystallization mainly because of their ability to form small protein-detergent complexes. In a previous study, we introduced glucose neopentyl glycol (GNG) amphiphiles with a branched diglucoside structure that has facilitated high resolution crystallographic structure determination of several membrane proteins. Like other glucoside detergents, however, these GNGs were less successful than DDM in stabilizing membrane proteins, limiting their wide use in protein structural study. As a strategy to improve GNG efficacy for protein stabilization, we introduced two different alkyl chains (i.e., main and pendant chains) into the GNG scaffold while maintaining the branched diglucoside head group. Of these pendant-bearing GNGs (P-GNGs), three detergents (GNG-2,14, GNG-3,13 and GNG-3,14) were not only notably better than both DDM (a gold standard detergent) and the previously described GNGs at stabilizing all six membrane proteins tested here, but were ahere including two GPCRs. In addition, the new detergents were as efficient as DDM at extracting membrane proteins, enabling use of these detergents over the multiple steps of protein isolation. The key difference between the P-GNGs and other glucoside detergents, the presence of a pendant chain, is likely to be responsible for their markedly enhanced protein stabilization behavior.Regulatory T cell (Treg)-based therapeutics are receiving increased attention for their potential to treat autoimmune disease and prevent transplant rejection. Adoptively transferred Tregs have shown promise in early clinical trials, but cell-based therapies are expensive and complex to implement, and "off-the-shelf" alternatives are needed. Here, we investigate the potential of artificial antigen presenting cells (aAPCs) fabricated from a blend of negatively charged biodegradable polymer (poly(lactic-co-glycolic acid), PLGA) and cationic biodegradable polymer (poly(beta-amino ester), PBAE) with incorporation of extracellular protein signals 1 and 2 and a soluble released signal 3 to convert naïve T cells to induced Foxp3+ Treg-like suppressor cells (iTregs) both in vitro and in vivo in a biomimetic manner. The addition of PBAE to the aAPC core increased the conjugation efficiency of signal proteins to the particle surface and resulted in enhanced ability to bind to naïve T cells and induce iTregs with potentely charged biodegradable polymer, poly(beta-amino ester), along with key biomolecular signals extracellularly presented protein signals 1 and 2 and a soluble released signal 3. These TolAPCs bind to naïve T cells and induce Foxp3+ Treg-like suppressor cells with potent suppressive function. In both in vitro and in vivo studies, it is shown that this non-cellular approach is useful to induce tolerance.Lung cancer is the leading cause of cancer-related deaths worldwide. Patients with resectable non-small cell lung cancer (NSCLC) are often treated with surgery and adjuvant chemotherapy. However, these patients continue to have a high risk of recurrence and death. Unfortunately, there has been little progress in the treatment of resectable NSCLC over the last several decades. Neoadjuvant therapy, which has been considered an approach to improve survival for resectable NSCLC patients, is a hotly debated topic. A systematic review of 32 randomized trials involving 10,000 patients demonstrated that there was no difference in survival between pre and post-operative chemotherapy. Because of such results, and the theoretical concern about resectable tumors progressing on relatively ineffective neoadjuvant chemotherapy and thus becoming unresectable, neoadjuvant chemotherapy fell out of favor and many clinicians preferred adjuvant chemotherapy post-surgery. Neoadjuvant therapy has however been revived in the last couple of years following emerging data from various ongoing trials suggesting that neoadjuvant immunotherapy may have significant efficacy and could potentially improve survival of patients with resectable NSCLC. In this review article, we discuss the evidence supporting the role of neoadjuvant immunotherapy in the multimodality management of resectable NSCLC. We summarize early results of ongoing clinical trials, and highlight the challenges in adopting a uniform definition of treatment "success." We address hurdles to be overcome in order to seek regulatory approval for neoadjuvant immunotherapy and establish it as a standard of care. Finally we provide some perspectives for the future.Immune checkpoint inhibitor therapies have revolutionized the management of patients with non-small cell lung carcinoma (NSCLC) and have led to unprecedented improvements in response rates and survival in a subset of a patients with this fatal disease. However, the available therapies work only for a minority of patients, are associated with substantial societal cost, and may lead to significant immune-related adverse events. Therefore, patient selection must be optimized through use of relevant biomarkers. PD-L1 protein expression by immunohistochemistry is widely used today for selection of PD-1 inhibitor therapy in NSCLC patients, however this approach lacks both robust sensitivity and specificity for predicting response. Tumor mutation burden (TMB), or the number of somatic mutations derived from next generation sequencing techniques, has been widely explored as an alternative or complementary biomarker for response to immune checkpoint inhibitors. In theory, a higher TMB increases the probability of tumon of response to immune checkpoint inhibitor therapy will likely require integration of TMB with a host of other potential biomarkers, including tumor genomic driver alterations, tumor-immune milieu, and other features of the host immune system. This perspective piece will review the current clinical evidence for TMB as a biomarker and address the technical sequencing considerations and ongoing challenges to use of TMB in routine practice.Neurofilament light chain (NfL) is a protein that is selectively expressed in neurons. Increased levels of NfL measured in either cerebrospinal fluid or blood is thought to be a biomarker of neuronal damage in neurodegenerative diseases. However, there have been limited investigations relating NfL to the concurrent measures of white matter (WM) decline that it should reflect. White matter damage is a common feature of Alzheimer's disease. https://www.selleckchem.com/products/bay-985.html We hypothesized that serum levels of NfL would associate with WM lesion volume and diffusion tensor imaging (DTI) metrics cross-sectionally in 117 autosomal dominant mutation carriers (MC) compared to 84 non-carrier (NC) familial controls as well as in a subset (N = 41) of MC with longitudinal NfL and MRI data. In MC, elevated cross-sectional NfL was positively associated with WM hyperintensity lesion volume, mean diffusivity, radial diffusivity, and axial diffusivity and negatively with fractional anisotropy. Greater change in NfL levels in MC was associated with larger changes in fractional anisotropy, mean diffusivity, and radial diffusivity, all indicative of reduced WM integrity.